BR112022015921A2 - Terapia gênica para tratar o transtorno de deficiência de cdkl5 - Google Patents
Terapia gênica para tratar o transtorno de deficiência de cdkl5Info
- Publication number
- BR112022015921A2 BR112022015921A2 BR112022015921A BR112022015921A BR112022015921A2 BR 112022015921 A2 BR112022015921 A2 BR 112022015921A2 BR 112022015921 A BR112022015921 A BR 112022015921A BR 112022015921 A BR112022015921 A BR 112022015921A BR 112022015921 A2 BR112022015921 A2 BR 112022015921A2
- Authority
- BR
- Brazil
- Prior art keywords
- gene therapy
- treat
- deficiency disorder
- cdkl5 deficiency
- raav
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11022—Cyclin-dependent kinase (2.7.11.22)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062976483P | 2020-02-14 | 2020-02-14 | |
| US202063090492P | 2020-10-12 | 2020-10-12 | |
| PCT/US2021/017656 WO2021163322A1 (en) | 2020-02-14 | 2021-02-11 | Gene therapy for treating cdkl5 deficiency disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022015921A2 true BR112022015921A2 (pt) | 2022-10-04 |
Family
ID=74873804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022015921A BR112022015921A2 (pt) | 2020-02-14 | 2021-02-11 | Terapia gênica para tratar o transtorno de deficiência de cdkl5 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230054144A1 (https=) |
| EP (1) | EP4103724A1 (https=) |
| JP (1) | JP2023514204A (https=) |
| KR (1) | KR20220140537A (https=) |
| CN (1) | CN115151648A (https=) |
| AU (1) | AU2021218703A1 (https=) |
| BR (1) | BR112022015921A2 (https=) |
| CA (1) | CA3164714A1 (https=) |
| IL (1) | IL294781A (https=) |
| MX (1) | MX2022009982A (https=) |
| TW (1) | TWI904135B (https=) |
| WO (1) | WO2021163322A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021202532A1 (en) * | 2020-03-31 | 2021-10-07 | Ultragenyx Pharmaceutical Inc. | Gene therapy for treating propionic acidemia |
| IL297635A (en) * | 2020-04-27 | 2022-12-01 | Univ Pennsylvania | Compositions useful in treatment of cdkl5 deficiency disorder (cdd) |
| WO2022225978A1 (en) * | 2021-04-21 | 2022-10-27 | The Regents Of The University Of California | Use of a split dcas fusion protein system for epigenetic editing |
| EP4387641A4 (en) * | 2021-08-18 | 2025-07-09 | Ultragenyx Pharmaceutical Inc | RECOMBINANT AAV FORMULATIONS |
| EP4349365A1 (en) * | 2022-10-07 | 2024-04-10 | Hansa Biopharma AB | Co-treatment for gene therapy |
| CN116350801A (zh) | 2022-11-22 | 2023-06-30 | 四川至善唯新生物科技有限公司 | 一种重组腺相关病毒载体的药物组合物及其用途 |
| CN116377050A (zh) * | 2022-12-16 | 2023-07-04 | 湖南家辉生物技术有限公司 | 一种发育性癫痫性脑病2型致病基因cdkl5突变位点的应用及其检测试剂和应用 |
| WO2024238958A1 (en) | 2023-05-18 | 2024-11-21 | Ultragenyx Pharmaceutical Inc. | Formulations comprising recombinant aav and methods of administering the same |
| WO2025122548A1 (en) * | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of disorders related to cdkl5 deficiency |
| WO2025155923A1 (en) | 2024-01-17 | 2025-07-24 | The Broad Institute, Inc. | Aav capsid modifications that enable improved cns-wide gene delivery through interactions with the transferrin receptor |
| WO2025217163A2 (en) | 2024-04-08 | 2025-10-16 | The Broad Institute, Inc. | Novel aav capsids binding to human cd59 |
| WO2025217174A1 (en) | 2024-04-08 | 2025-10-16 | The Broad Institute, Inc. | Aav capsid modifications that enable improved cns-wide gene delivery through interactions with carbonic anhydrase iv |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2140408B (en) | 1982-12-23 | 1987-03-18 | Suwa Seikosha Kk | Process for producing quartz glass |
| NZ532635A (en) | 2001-11-13 | 2007-05-31 | Univ Pennsylvania | A method of identifying unknown adeno-associated virus (AAV) sequences and a kit for the method |
| DK2359869T3 (en) | 2001-12-17 | 2019-04-15 | Univ Pennsylvania | Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof |
| DE602004030327D1 (de) | 2003-05-21 | 2011-01-13 | Genzyme Corp | Verfahren zur herstellung von präparationen rekombinanter aav-virionen, die weitgehend frei von leeren capsiden sind |
| SI3235827T1 (sl) | 2003-06-19 | 2021-05-31 | Genzyme Corporation | AAV virioni z zmanjšano imunoreaktivnostjo in uporaba za ta namen |
| US9441244B2 (en) | 2003-06-30 | 2016-09-13 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
| CN1856576B (zh) | 2003-09-30 | 2011-05-04 | 宾夕法尼亚州立大学托管会 | 腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用 |
| WO2006110689A2 (en) | 2005-04-07 | 2006-10-19 | The Trustees Of The University Of Pennsylvania | Method of increasing the function of an aav vector |
| DK2191001T3 (en) | 2007-04-09 | 2016-09-19 | Univ Florida | RAAV VECTOR COMPOSITIONS WITH TYROSIN MODIFIED CAPSIDE PROTEINS AND PROCEDURES FOR USE THEREOF |
| US9611302B2 (en) | 2007-04-09 | 2017-04-04 | University Of Florida Research Foundation, Inc. | High-transduction-efficiency RAAV vectors, compositions, and methods of use |
| US9725485B2 (en) | 2012-05-15 | 2017-08-08 | University Of Florida Research Foundation, Inc. | AAV vectors with high transduction efficiency and uses thereof for gene therapy |
| DK2242840T3 (da) | 2008-01-29 | 2019-10-21 | Applied Genetic Tech Corporation | Produktion af rekombinant adeno-associeret virus under anvendelse af bhk-celler i suspension |
| US8679837B2 (en) | 2009-04-02 | 2014-03-25 | University Of Florida Research Foundation, Inc. | Inducible system for highly efficient production of recombinant Adeno-associated virus (rAAV) vectors |
| WO2010138263A2 (en) | 2009-05-28 | 2010-12-02 | University Of Massachusetts | Novel aav 's and uses thereof |
| DK2529020T3 (en) | 2010-01-28 | 2018-08-06 | Childrens Hospital Philadelphia | SCALABLE PREPARATION PLATF FOR CLEANING VIRAL VECTORS AND CLEANED VIRAL VECTORS FOR USE IN GENTHERAPY |
| US8927514B2 (en) | 2010-04-30 | 2015-01-06 | City Of Hope | Recombinant adeno-associated vectors for targeted treatment |
| ES2685611T3 (es) | 2011-02-14 | 2018-10-10 | The Children's Hospital Of Philadelphia | Vector VAA8 mejorado con una actividad funcional aumentada y métodos de utilización del mismo |
| HRP20171334T1 (hr) | 2011-04-22 | 2017-11-17 | The Regents Of The University Of California | Virioni adeno-povezanog virusa s kapsid varijantom i postupci njihove upotrebe |
| AU2013249202B2 (en) | 2012-04-18 | 2018-08-09 | The Children's Hospital Of Philadelphia | Composition and methods for highly efficient gene transfer using AAV capsid variants |
| US10294281B2 (en) | 2012-05-15 | 2019-05-21 | University Of Florida Research Foundation, Incorporated | High-transduction-efficiency rAAV vectors, compositions, and methods of use |
| US10266845B2 (en) | 2013-02-08 | 2019-04-23 | The Trustees Of The University Of Pennsylvania | Enhanced AAV-mediated gene transfer for retinal therapies |
| US9585971B2 (en) | 2013-09-13 | 2017-03-07 | California Institute Of Technology | Recombinant AAV capsid protein |
| BR112017005892A2 (pt) | 2014-09-24 | 2017-12-12 | Hope City | variantes de vetor de vírus adeno-associado para edição de genoma de alta eficácia e métodos da mesma |
| GB201502305D0 (en) | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| GB201502306D0 (en) | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| US10081659B2 (en) | 2015-04-06 | 2018-09-25 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Adeno-associated vectors for enhanced transduction and reduced immunogenicity |
| US10385320B2 (en) | 2015-12-02 | 2019-08-20 | The Board Of Trustees Of The Leland Stanford Junior University | Recombinant adeno-associated virus capsids with enhanced human skeletal muscle tropism |
| ES2877754T3 (es) | 2016-02-04 | 2021-11-17 | Genovis Ab | Nuevas proteasas estreptocócicas |
| US10179176B2 (en) | 2016-02-16 | 2019-01-15 | The Board Of Trustees Of The Leland Stanford Junior University | Recombinant adeno-associated virus capsids resistant to pre-existing human neutralizing antibodies |
| WO2017165859A1 (en) | 2016-03-24 | 2017-09-28 | Research Institute At Nationwide Children's Hospital | Modified viral capsid proteins |
| EP3827812B1 (en) | 2016-07-29 | 2025-10-29 | The Regents of the University of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
| AU2018224044B2 (en) | 2017-02-21 | 2024-01-25 | The Uab Research Foundation | Modified AAV capsid proteins and uses thereof |
| CA3056410A1 (en) * | 2017-03-15 | 2018-09-20 | Ovid Therapeutics, Inc. | Use of designer receptors exclusively activated by designer drugs in the treatment of seizure disorders |
| CA3063464A1 (en) * | 2017-05-19 | 2018-11-22 | Encoded Therapeutics, Inc. | High activity regulatory elements |
| WO2018222503A1 (en) | 2017-05-31 | 2018-12-06 | The Regents Of The University Of California | Adeno-associated virus with variant capsid and methods of use thereof |
| CA3065946A1 (en) | 2017-06-05 | 2018-12-13 | Research Institute At Nationwide Children's Hospital | Enhanced modified viral capsid proteins |
| US20210228738A1 (en) | 2017-07-17 | 2021-07-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
| IL276859B2 (en) * | 2018-02-27 | 2025-12-01 | Univ Pennsylvania | Novel adeno-associated virus (aav) vectors, aav vectors having reduced capsid deamidation and uses therefor |
| AU2020215682B2 (en) | 2019-01-28 | 2025-12-18 | Duke University | Compositions and methods for evading humoral immunity |
| US12544437B2 (en) * | 2019-10-04 | 2026-02-10 | Ultragenyx Pharmaceutical Inc. | Methods for improved therapeutic use of recombinant AAV |
-
2021
- 2021-02-11 MX MX2022009982A patent/MX2022009982A/es unknown
- 2021-02-11 KR KR1020227029963A patent/KR20220140537A/ko active Pending
- 2021-02-11 JP JP2022548652A patent/JP2023514204A/ja active Pending
- 2021-02-11 BR BR112022015921A patent/BR112022015921A2/pt unknown
- 2021-02-11 IL IL294781A patent/IL294781A/en unknown
- 2021-02-11 WO PCT/US2021/017656 patent/WO2021163322A1/en not_active Ceased
- 2021-02-11 CN CN202180013079.XA patent/CN115151648A/zh active Pending
- 2021-02-11 CA CA3164714A patent/CA3164714A1/en active Pending
- 2021-02-11 AU AU2021218703A patent/AU2021218703A1/en active Pending
- 2021-02-11 US US17/796,064 patent/US20230054144A1/en active Pending
- 2021-02-11 EP EP21711979.1A patent/EP4103724A1/en active Pending
- 2021-02-17 TW TW110105391A patent/TWI904135B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| TWI904135B (zh) | 2025-11-11 |
| KR20220140537A (ko) | 2022-10-18 |
| AU2021218703A1 (en) | 2022-07-28 |
| US20230054144A1 (en) | 2023-02-23 |
| JP2023514204A (ja) | 2023-04-05 |
| MX2022009982A (es) | 2022-09-12 |
| TW202144577A (zh) | 2021-12-01 |
| WO2021163322A1 (en) | 2021-08-19 |
| CA3164714A1 (en) | 2021-08-19 |
| CN115151648A (zh) | 2022-10-04 |
| EP4103724A1 (en) | 2022-12-21 |
| IL294781A (en) | 2022-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022015921A2 (pt) | Terapia gênica para tratar o transtorno de deficiência de cdkl5 | |
| Beug et al. | Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma | |
| BR112022015979A2 (pt) | Vetores de terapia genética para tratamento de doenças cardíacas | |
| Nakhaei et al. | The E3 ubiquitin ligase Triad3A negatively regulates the RIG-I/MAVS signaling pathway by targeting TRAF3 for degradation | |
| AR116569A1 (es) | Terapia génica para tratar la acidemia propiónica | |
| PH12020551096A1 (en) | A modified raav capsid protein for gene therapy | |
| BR112019000015A2 (pt) | distribuição por vírus oncolítico pseudotipado de polipeptídeos terapêuticos | |
| BR112018071167A2 (pt) | entrega de beta-sarcoglicano e microrna-29 por vírus adenoassociado e tratamento de distrofia muscular | |
| BR112022022644A2 (pt) | Composições de vírus adeno-associados compatíveis com espécies cruzadas e método de uso destas | |
| BR112023002951A2 (pt) | Compostos de fosfolipídio e usos destes | |
| CO2020003187A2 (es) | Rnai variante | |
| Schirrmacher et al. | Long‑term remission of prostate cancer with extensive bone metastases upon immuno‑and virotherapy: A case report | |
| PH12022550109A1 (en) | Modified aav capsid proteins for treatment of arthritic disease | |
| BR112023002904A2 (pt) | Vírus adenoassociado recombinante para tratar neurodegeneração com início na idade adulta associada a grn | |
| EA202290001A1 (ru) | Векторы aav с промотором миелинового белка ноль и их применение для лечения заболеваний, связанных со шванновскими клетками, таких как болезнь шарко-мари-тута | |
| ZA202400124B (en) | Pharmaceutical composition of non-enveloped virus | |
| CY1118840T1 (el) | Πρωτοτυπα πεπτιδια για θεραπευτικη και προληπτικη αγωγη ανοσοσχετιζομενων διαταραχων, που περιλαμβανει θεραπευτικη και προληπτικη αγωγη λοιμωξης διαμορφωνοντας εγγενη ανοσια | |
| BR112022014552A2 (pt) | Polipeptídeo recombinante, composição farmacêutica, método de prevenção ou tratamento de uma infecção viral em um indivíduo que necessita do mesmo, molécula de rna, composição terapêutica, sistema de expressão, polipeptídeo recombinante para tratar infecção por sars-cov-2 e polinucleotídeo que codifica o polipeptídeo recombinante | |
| BR112019023064A2 (pt) | tratamento de carcinoma hepatocelular | |
| CO2024006328A2 (es) | Composiciones útiles en el tratamiento del trastorno por deficiencia de cdkl5 (cdd) | |
| AR121709A1 (es) | Terapia génica para tratar la acidemia propiónica | |
| CO2022016956A2 (es) | Composiciones útiles en el tratamiento del trastorno de deficiencia de cdkl5 (cdd) | |
| ZA202409276B (en) | Aav vector encoding diamine oxidase and uses thereof | |
| US8268974B2 (en) | Process to produce fibrillar proteins | |
| BR112022007923A2 (pt) | Anticorpo recombinante isolado ou fragmento de ligação ao antígeno deste, composição farmacêutica, molécula de polinucleotídeo, vetor, célula, e, método para prevenir, tratar ou melhorar pelo menos um sintoma da infecção por influenza |